title: [Pegylated intereferon hematological safety in comparison with standard].
abstract: Comparative analysis of adverse hematologic effects in 135 patients with with chronic hepatits C on combined antiviral therapy of pegylated and "short lived" forms of alpha-interferon in combination with ribavirin was investigated. As a result of the comparison, the response to antiviral therapy in patients with chronic hepatitis C treated with daily administration of simple interferon-alpha in hematologic data is similar in patients undergoing treatment with pegylated drugs.
authors: V Kh
authors: VKh
authors: Fazylov
authors: É R
authors: ÉR
authors: Manapova
authors: S V
authors: SV
authors: Tkacheva
authors: Iu M
authors: IuM
authors: Sozinova
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced* / Q000628:therapy; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D012254:Ribavirin / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a